nVerses Capital’s Keros Therapeutics KROS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-13,124
Closed -$140K – 134
2026
Q2
$140K Buy
+13,124
New +$146K 0.22% 223

Other funds holding KROS

nVerses Capital's KROS Position: Q3 2026 in Review

nVerses Capital sold out of Keros Therapeutics (KROS) in Q3 2026, closing a stake of 13,124 shares — an estimated $140K sold.

nVerses Capital first reported a position in KROS in Q2 2026 and held it in 1 quarter. The position peaked at $140K in Q2 2026. 135 funds tracked by Wall St. Rank hold KROS as of Q3 2026.

  • nVerses Capital reported no remaining Keros Therapeutics position as of Q3 2026 after selling out during the quarter.
  • nVerses Capital sold 13,124 Keros Therapeutics shares in Q3 2026, an estimated $140K.
  • nVerses Capital first reported a position in Keros Therapeutics in Q2 2026 and held it in 1 quarter.
  • nVerses Capital's Keros Therapeutics position peaked at $140K in Q2 2026.
  • 135 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2026.

Based on nVerses Capital's 13F filing for Q3 2026.